Annexon Q2 Earnings Call Highlights
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label. President and Chief Executive Officer Doug Love said the company's two lead programs are approaching
Prepared by Christopher Adams and reviewed by editorial team.
- Articles Published:
- 19
- Right Leaning:
- 0
- Left Leaning:
- 0
- Neutral:
- 19
- Distribution:
- Left 0%, Center 100%, Right 0%
Left: Highlights potential patient benefits and regulatory safety mechanisms for clinical therapies. Center: Reports financial loss, EPS miss, cash balance, and clinical timelines. Right: Emphasizes market reaction, capital burn rate, and non-dilutive debt financing.
Corporate press release detailing Q2 2026 financial updates and trial changes on August 12, 2026 at 06:58 AM EDT. https://www.globenewswire.com/news-release/2026/08/12/3343458/0/en/annexon-expands-vonaprument-phase-3-program-in-geographic-atrophy-with-addition-of-month-24-dual-primary-endpoint-complementing-month-15-primary-endpoint-and-launch-of-open-label-e.html
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Annexon Q2 Earnings Call Highlights
EventRegistry Kalkinemedia Finanznachrichten Stocktitan Investing Marketbeat Globenewswire Annexonbio Stocktitan Investing Investing Tradingview Neurologylive Biospace Marketwatch Yahoo Tipranks Seekingalpha MarketbeatFrom Right
No right-leaning sources found for this story.
Comments